RO INTRODUCES ONE-MONTH $199 WEGOVY NEW PATIENT OFFER AND DISCOUNTED BODY MEMBERSHIP
Patients can come to Ro for the lowest cost FDA-approved GLP-1s anywhere
To make it easier for patients to get started, Ro is also offering a discounted first month fee of
"Through our collaboration with Ro, we are able to further expand access to authentic, FDA-approved Wegovy®. Pairing this one-month
"Working with Novo Nordisk, we can uniquely offer the most convenient and affordable path for patients seeking access to FDA-approved GLP-1s," said
Ro's obesity care formulary is one the most comprehensive of any telehealth company, integrating branded cash pay and insurance-eligible options that can be picked up at a retail pharmacy or delivered to one's home. With Ro's GLP-1 Insurance Checker, anyone can verify their benefits coverage for free and find the best possible medication choice at the lowest possible price – whether that's using insurance coverage or paying cash. To date, Ro has helped hundreds of thousands of people understand their benefits coverage to get the best medication for them.
For more information on Ro's Body Membership and full suite of GLP-1 options, visit Ro.co/weightloss.
About Ro
Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the easiest, most effective care possible. Ro is the only company to offer nationwide telehealth, labs, and pharmacy services. This is enabled by Ro's vertically integrated platform that helps patients achieve their goals through a convenient, end-to-end healthcare experience spanning from diagnosis, to delivery of medication, to ongoing care. Since 2017, Ro has helped millions of patients, including one in every county in
See Important Safety Information about GLP-1 medications, including Boxed Warning, at ro.co/safety-info/glp1
Contact: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/ro-introduces-one-month-199-wegovy-new-patient-offer-and-discounted-body-membership-302462669.html
SOURCE Ro
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
- Apeing Presale Surpasses $80,000 as Stage 3 Progresses Toward Scheduled Stage 4 Launch
- Agog-Supported Works Win Two of Three Immersive Prizes at the 83rd Venice International Film Festival
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share